3 High-Yielding Dividend Growth Stocks That Can Generate Passive Income for Your Portfolio for Years

The article highlights three dividend-oriented stocks—AbbVie, Home Depot and ExxonMobil—with yields ranging from 2.7% to 3.5% as long-term income plays. AbbVie (yield ~2.9%) reported sales up 8% to $44.5 billion through nine months and recent dividend growth of 5.5%, driven by Skyrizi and Rinvoq generating $18.5 billion vs Humira's $3.3 billion quarterly; Home Depot yields 2.7%, has raised its dividend 16 consecutive years, expects ~3% sales growth for the fiscal year and shares are down ~13% YTD; Exxon yields 3.5%, has grown its dividend for 43 years, reported YTD earnings of $22.3 billion (down $3.7B) with EPS $5.16 vs annual dividends of $4.12 and trades at roughly 16x forward estimates.

Analysis

Market structure: High-quality dividend names (ABBV, XOM, HD) act as defensive yield anchors and will attract rotational inflows if rates stabilize; AbbVie’s pivot from Humira to Skyrizi/Rinvoq ($18.5B YTD vs Humira $3.3B/qtr) reduces single-product risk and strengthens pricing power in immunology, while Exxon’s cash generation (EPS $5.16 vs annual dividend $4.12) gives it optionality in capex/dividends. Weak discretionary demand pressures Home Depot’s comps (shares -13% YTD) and compresses pricing power short-term, benefiting cheaper competitors or private-label suppliers.

Risk assessment: Key tail risks are regulatory/biosimilar erosion for ABBV (material revenue hit >20% if major biosimilar uptake), an oil price collapse (>-30% move) that would strain XOM free cash flow, and a consumer recession that would push HD comps negative >5% YoY. Immediate risks (days–weeks): earnings/guidance and OPEC meetings; short-term (months): holiday comps and FDA decisions; long-term (years): drug patent cliffs and energy transition forcing capex reallocation. Hidden dependency: ABBV’s payout durability depends on continued Skyrizi/Rinvoq growth and successful pipeline launches; XOM’s dividend is cyclical despite coverage today.

Trade implications: Direct plays – accumulate ABBV on 5–10% dips (dividend + pipeline optionality) and core-buy XOM for yield+value (target P/E ~16); use covered-call overlays on XOM to boost income. Pair trades – long ABBV vs short volatile small-cap biotech (XBI) isolates dividend-quality immunology growth. Options – for HD, prefer a protective 3–6 month put spread to hedge or a 9–12 month call spread to express recovery with defined risk. Rotate modestly (3–5% reweight) from low-yield growth into high-quality dividend names over 1–3 months.

Contrarian angles: Consensus underestimates AbbVie’s secular re-rating if Skyrizi/Rinvoq sustain >15% annual growth — consensus upgrades could add 15–25% upside in 12 months. Home Depot’s selloff may be overdone if repair/maintenance spend holds, creating a tactical buy-on-improvement in comps (>+1% MoM over two months). Conversely, XOM’s resilience masks transition risk: a multi-year move to lower oil demand could compress multiples despite current cash coverage. Unintended consequence: chasing yield now could leave portfolios exposed to idiosyncratic regulatory shocks unique to healthcare and fossil fuels.

Key Decisions for Investors

• Establish a 2–3% long position in AbbVie (ABBV) on any 5–10% price dip or if dividend yield rises to ≥3.5%; set a 12% stop-loss and a 12-month target total return of ~15–20%; monitor FDA decisions and quarterly Skyrizi/Rinvoq growth over next 90 days as primary catalysts.
• Allocate 3–4% to ExxonMobil (XOM) as a core income holding; implement a 6–9 month covered-call strategy selling calls 8–12% OTM to boost cash yield while retaining upside; buy 6-month protective puts if Brent drops below $70 or XOM trades >12% lower to ladder entry.
• Do not increase Home Depot (HD) exposure above 1–2% until holiday comps and November/December same-store-sales print positive for two consecutive months; instead buy a 3–6 month put spread (buy 10% OTM, sell 5% OTM) to hedge existing exposure or initiate a 9–12 month call spread (defined-cost recovery play) if comps stabilize.
• Implement a relative-value trade: long ABBV 2.0% vs short XBI (small-cap biotech ETF) 1.5% to capture dividend-quality outperformance; rebalance after 3 months or on major FDA/regulatory news that changes biotech volatility regime.